CHAIN Biotechnology is an immuno-therapeutics company based at MediCity Nottingham.
CHAIN develops live biotherapeutic products that can be delivered directly to the lower gastrointestinal tract.
Using our knowledge of the gut microbiota and expertise in engineering biology and fermentation we have built a proprietary and highly differentiated Clostridium Assisted Drug Delivery platform (CADDTM) for vaccine and therapeutic development.
CHAIN’s technology is based on a single, but highly effective, Clostridium strain engineered to deliver a specific therapeutic modality, whilst also secreting metabolites that play key roles in gut and immune system homeostasis. The engineered strains deliver and produce the therapeutics in situ during growth in the lower gastrointestinal tract, impacting on the mucosal immune system.
Clostridia are a dominant class of beneficial anaerobic bacteria found in the human gut and serve as an ideal live biotherapeutics delivery system, supporting oral drug delivery that is targeted, safe and controllable. In addition, our live biotherapeutics can be manufactured easily and cost-effectively and are highly stable with no need for cold chain logistics. We overcome many of the challenges associated with oral drug delivery.
Board and Management Team
Dr Nel Moore
Executive Chair
Nel has considerable experience in drug development with a track record taking therapeutics to market. She is former Global Product Vice President at AstraZeneca, where she built up and led the antibiotics development organisation as part of a semi-autonomous internal antibiotics business unit.
Dr Steve Emery
Chief Scientific Officer
Steve is the former Executive Director and Head of Global Due Diligence at AstraZeneca.
He has an extensive background in oncology research & development, with over 40 yrs experience in drug discovery & development.
Andrea Harrison
Chief Financial Officer
Andrea is a chartered accountant with more than 30 years experience in life sciences across pharma and biotech, public and private sector. She holds significant experience of R&D project financing, collaborations & transactions.
Dr Edward Green
Founder, Board Member
Edward is a serial entrepreneur with over 25 years experience with anaerobic bacteria. He participates in the IB Leadership Forum, several NIBB management boards and advisory panels for Bioenergy and Biotechnology.
Zahid Bashir
Non-Executive Director
Zahid has over 16 years of clinical and drug development spanning Roche, BMS and Kite. He has overseen the successful regulatory approval of several innovative drugs, including cell and gene therapy products, in the US and Europe.
Advisory Team
Dr Mark Edwards
Mark is a Molecular Biologist with 40 years experience in biotherapeutic research and development. Formerly CSO at British Biotech and Oxagen, his expertise ranges from metabolic pathway engineering to vaccine development.